PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment

Journal of Cellular Physiology

Volumn 202, Issue 3, 2005, Pages 900-911

  Zauli, Giorgio ^a   Sancilio, Silvia ^b   Cataldi, Amelia ^b   Sabatini, Nadia ^b   Bosco, Domenico ^c   Di Pietro, Roberta ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Ist Citomorfologia Um Normale P   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETONE DERIVATIVE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL DEATH; CELL SURVIVAL; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL SURVIVAL; CHROMONES; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; I-KAPPA B PROTEINS; JURKAT CELLS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, IMMUNOELECTRON; MORPHOLINES; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12944333065     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20202     Document Type: Article

References (59)

1. Armitage RJ. 1994. Tumor necrosis factor receptor superfamily members and their ligands. Curr Opin Immunol 6(3):407-413.
2. Ashkenazi A, Dixit VM. 1999. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 11:255-260.
3. Baetu TM, Hiscott J. 2002. On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13:199-207.
4. Baker SJ, Reddy EP. 1996. Transducer of life and death: TNF receptor superfamily and associated proteins. Oncogene 12:1-9.
5. Beraud C, Henzel WJ, Baeuerle PA. 1999. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation. Proc Natl Acad Sci USA 96:429-434.
6. Bortul R, Tazzurri PL, Cappellini A, Tabellini G, Billi AM, Bareggi R, Manzoli L, Cocco L, Martelli AM. 2003. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIP(L) up-regulation. Leukemia 17:379-389.
7. Bottero V, Rossi F, Samson M, Mari M, Hofman P. 2001. IκB-α, the NF-κB inhibitory subunit, interacts with ANT, the mitochondrial ATP/ADP translocator. J Biol Chem 24:21317-21324.
8. Canty TG, Jr., Boyle EM, Jr., Farr A, Morgan EN, Verrier ED, Pohlman TH. 1999. Oxidative stress induces NF-kappaB nuclear translocation without degradation of IkappaBalpha. Circulation 100(Suppl 19):II361-II364.
9. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frish S, Reed JC. 1998. Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318-1321.
10. Cataldi A, Miscia S, Centurione L, Rapino M, Bosco D, Grifone G, Valerio VD, Garaci F, Rana R. 2002. Role of nuclear PKC delta in mediating caspase-3-upregulation in Jurkat T leukemic cells exposed to ionizing radiation. J Cell Biochem 86(3):553-560.
11. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. 1997. Death receptor B, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7:821-830.
12. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK. 2001. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20:6073-6083.
13. Chen X, Kandasamy K, Srivastava RK. 2003. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 63:1059-1066.
14. Chou A-H, Tsai H-F, Lin S-L, Hsu P-I, Hsu P-N. 2001. Enhanced proliferation and increased IFN-γ production in T cells by signal transduced through TNF-related apoptosis-inducing ligand. J Immunol 167:1347-1352.
15. Clodi K, Wimmer D, Li Y, Goodwin R, Jaeger U, Mann G, Gadner H, Younes A. 2000. Expression of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 111:580-586.
16. Datta SR, Brunet A, Greenberg ME. 1999. Cellular survival: A play in three Akts. Genes Dev 13(22):2905-2927.
17. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. 1997a. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 186:1165-1170.
18. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. 1997b. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7:813-820.
19. Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K, Zamai L, Miscia S, Zauli G. 2001. Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1. Blood 97(9):2596-2603.
20. Didonato JA, Mercurio F, Karin M. 1995. Phosphorylation of IκBα precedes but is not sufficient for its dissociation from NF-κB. Mol Cell Biol 15:1302-1311.
21. Downward J. 1998. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10(2):262-267.
22. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin K-M, Jeremias I. 2003. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 22:3842-3852.
23. Feng Y, Fratkin JD, LeBlanc MH. 2003. Inhibiting caspase-9 after injury reduces hypoxic ischemic neuronal injury in the cortex in the newborn rat. Neurosci Lett 344(3):201-204.
24. Gibson EM, Henson ES, Haney N, Villanueva J, Gibson SB. 2002. Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c release. Cancer Res 62:488-496.
25. Hu WH, Johnson H, Shu HB. 1999. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J Biol Chem 274:30603-30610.
26. Jang Y-J, Park KS, Chung H-Y, Kim H-Il. 2003. Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. Cancer Lett 194:107-117.
27. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 1:82-89.
28. Kawai H, Nie L, Yuan ZM. 2002. Inactivation of NF-kappaB-dependent cell survival, a novel mechanism for the proapoptotic function of c-Abl. Mol Cell Biol 22(17):6079-6088.
29. Laffargue M, Raynal P, Yart A, Peres C, Wetzker R, Roche S, Payrastre B, Chap H. 1999. An epidermal growth factor receptor/Gab1 signaling pathway is required for activation of phosphoinositide 3-kinase by lysophosphatidic acid. J Biol Chem 274(46):32835-32841.
30. LeBlanc HN, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66-75.
31. Lee NS, Cheong HJ, Kim SJ, Kim SE, Kim CK, Lee KT, Park SK, Baick SH, Hong DS, Park HS, Won JH. 2003. Ex vivo purging of leukemia cells using tumor-necrosis-factor-felated apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 17(7):1375-1383.
32. Lin YZ, Yao SY, Vesch RA, Torgerson TR, Hawiger J. 1995. Inhibition of nuclear translocation factor NF-kappa B by a synthetic peptide containing a cell-membrane permeable motif and nuclear localization sequence. J Biol Chem 270:14255-14258.
33. MacFarlane M. 2003. TRAIL-induced signaling and apoptosis. Toxicol Lett 139:89-97.
34. Milani D, Zauli G, Rimondi E, Celeghini C, Marmiroli S, Narducci P, Capitani S, Secchiero P. 2003. Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126-135.
35. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. 1999. NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
36. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. 1997. An antagonist decoy receptor and a new death domain-containing receptor for TRAIL. Science 277:815-818.
37. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690.
38. Rokhlin OW, Guseva NV, Tagiyev AF, Glover RA, Cohen MB. 2002. Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 52:1-11.
39. Schneider P, Thome M, Burns K, Bodmer JL, Hofman K, Kataoka T, Holler N, Tschopp J. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-κB. Immunity 7:831-836.
40. Secchiero P, Bertolaso L, Casareto L, Gibellini D, Vitale M, Bemis K, Aleotti A, Capitani S, Franchini G, Gallo RC, Zauli G. 1998. Human herpesvirus 7 infection induces profound cell cycle perturbations coupled to dysregulation of cdc2 and cyclin B and polyploidization of CD4+ T cells. Blood 92:1685-1698.
41. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, Capitani S, Zauli G. 2001. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood 98:2220-2228.
42. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani D, Zauli G. 2002. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood 100:2421-2429.
43. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G. 2003. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107:2250-2256.
44. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277:818-821.
45. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. 2002. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem 277:3863-3869.
46. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. 1997. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol 99:618-624.
47. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. 1995. Rel/NF-κB/IκB family: Intimate tales of association and dissociation. Genes Dev 9:2723-2735.
48. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 18:5241-5248.
49. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. 1997. TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO J 16:5386-5397.
50. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH. 1999. Tumoricidal activity of tumor-necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
51. Wang D, Baldwin AS. 1998. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 273:29411-29416.
52. Weiner JA, Chun J. 1999. Schwann cell survival mediated by the signaling phospholipid lysophosphatidic acid. Proc Natl Acad Sci USA 96(9):5233-5238.
53. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Davis-Smith T, Rauch C, Smith CA, Goodwin RG. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682.
54. Wilson L, Szabo C, Salzman AL. 1999. Protein kinase C-dependent activation of NF-kappaB in enterocytes is independent of IkappaB degradation. Gastroenterology 117(1):106-114.
55. Yang X, Thiele CJ. 2003. Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma. Cancer Lett 197(1-2):137-143.
56. Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S. 2003. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukaemia cells proceed through a phosphatidylinositol-3-kinase/Akt-dependent process. Cancer Res 63(8):1822-1833.
57. Zamai L, Secchiero P, Pierpaoli S, Bassini A, Papa S, Alnemri ES, Guidotti L, Vitale M, Zauli G. 2000. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropopiesis. Blood 95:3716-3724.
58. Zauli G, Vitale M, Falcieri E, Gibellini D, Bassini A, Celeghini C, Columbaro M, Capitani S. 1997. In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 90:2234-2243.
59. Zauli G, Pandolfi A, Gonelli A, Di Pietro R, Guarnieri S, Ciabattoni G, Rana R, Vitale M, Secchiero P. 2003. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res 92:732-740.